Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 26, 2010

BioClinica Pads Clinical Trial Management Services with Acquisition of TranSenda

  • BioClinica is buying substantially all of the assets of TranSenda International for 577,960 shares of BioClinica unregistered common stock. Headquartered in Bellevue, WA, TranSenda is a provider of clinical trial management software (CTMS) solutions. For 2010, BioClinica expects TranSenda to contribute approximately $1 million in service revenue and an operating loss of $500,000.

    TranSenda’s suite of web-based, Office-Smart CTMS offerings, and patent-pending integration technologies create efficiencies for trial operations through interoperability with Microsoft Office tools. “TranSenda brings a line of Office-Smart clinical trial management solutions to BioClinica that will become a part of our Microsoft Office-enabled delivery vision,” says Mark Weinstein, CEO of BioClinica.

    “Information workers in the life sciences industry are often challenged with working across many different systems throughout the clinical trial process,” points out Michael Naimoli, director of life sciences industry solutions, Microsoft. “TranSenda has helped pharmaceutical companies address these problems, providing solutions that allow professionals to work within the familiar Microsoft Office environment.”

    Commenting on the takeover, Weinstein says, “This acquisition is an important step forward as we continue to advance our integrated eClinical solutions model and execute our strategy of bringing best-in-class technology and resources to our customers. The acquisition of TranSenda not only enhances our portfolio of clinical trial technology, it also provides us intellectual property with thought leaders and domain experts in trial planning and management.”

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »